Analysts Set OnKure Therapeutics, Inc. Price Target at $32.00

The clinical-stage biopharmaceutical company is advancing small molecule drug candidates for oncology and autoimmune diseases.

Mar. 12, 2026 at 7:52am

Got story updates? Submit your updates here. ›

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have earned a consensus 'Hold' recommendation from four ratings firms covering the company. The average 12-month price target among brokerages is $34.00. Institutional investors and hedge funds own 90.98% of the company's stock.

Why it matters

OnKure Therapeutics is a promising clinical-stage biotech focused on developing novel therapies for cancer and autoimmune diseases. The analyst price target and consensus rating provide insight into the market's view of the company's potential.

The details

OnKure Therapeutics is headquartered in Westlake Village, California and is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function. The company's lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.

  • OnKure Therapeutics shares are currently trading on the NASDAQ exchange.
  • Weiss Ratings restated a 'sell (d-)' rating on shares of OnKure Therapeutics on December 22nd.

The players

OnKure Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases.

Weiss Ratings

A ratings firm that provides independent research and analysis on financial products and services.

Got photos? Submit your photos here. ›

The takeaway

OnKure Therapeutics is a promising clinical-stage biotech company with a focus on developing innovative cancer and autoimmune therapies. The consensus 'Hold' rating and $34 price target from analysts suggest the market sees potential in the company's pipeline, though some firms remain cautious.